中国临床药理学与治疗学2026，Vol.31Issue(5)：649-657,9.DOI:10.12092/j.issn.1009-2501.2026.05.009
靶向OX40和OX40L单克隆抗体治疗特应性皮炎的研究进展
Research advances in targeting OX40/OX40L monoclonal antibodies for the treatment of atopic dermatitis
摘要
Abstract
Atopic dermatitis(AD)is a chronic in-flammatory skin disease characterized by a T helper cells(th)2-dominant immune response coupled with multifactorial immune dysregulation involving Th1,Th17,and Th22 pathways.Current therapeutic approaches confront significant clinical challenges,including suboptimal treatment responses in sub-sets of patients,safety risks associated with pro-longed pharmacotherapy,and compromised pa-tient adherence.Emerging evidence demonstrates that the OX40-OX40L signaling pathway orches-trates sustained immunoinflammatory responses through its regulatory role in antigen-presenting cell-T cell interactions.Monoclonal antibodies tar-geting this pathway effectively inhibit pathological immune activation,demonstrating dual clinical ben-efits of ameliorating cutaneous lesions and main-taining durable remission after treatment cessation.This review systematically elucidates the mechanis-tic involvement of the OX40-OX40L axis in AD pathogenesis and provides a comprehensive analy-sis of clinical trial advancements in anti-OX40/OX40L monoclonal antibody therapeutics.关键词
抗 OX40单克隆抗体/抗 OX40L 单克隆抗体/特应性皮炎/靶向治疗Key words
anti-OX40 monoclonal antibody/anti-OX40L monoclonal antibody/atopic dermatitis/tar-geted therapy分类
医药卫生引用本文复制引用
黄帆,丁紫嫣,周茜,胡丁元,聂小燕,丁锐,方翼..靶向OX40和OX40L单克隆抗体治疗特应性皮炎的研究进展[J].中国临床药理学与治疗学,2026,31(5):649-657,9.基金项目
北京市通州区科技计划项目(KJ2024CX058) （KJ2024CX058）
河北省创新能力提升计划项目(235A2601D) （235A2601D）
北京国际医药临床研发平台(2107000043) （2107000043）
